Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations | terminated | Phase 3 | 9 | University of UlmOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03473457 | CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia(AML) | terminated | N/A | 2 | Zhujiang HospitalOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | terminated | N/A | 6 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | terminated | Phase 1 | 12 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML(HINKL) | terminated | Phase 2 | 1 | Technische Universität DresdenOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | terminated | Phase 1 / Phase 2 | 22 | University of Illinois at ChicagoOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT03806192 | Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid Leukemia | terminated | N/A | 12 | University of WashingtonOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | terminated | Phase 4 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | terminated | N/A | 5 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT03125876 | A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 12 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03360006 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer | terminated | Phase 1 | 30 | AbbVieINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | terminated | Phase 1 / Phase 2 | 1 | Fox Chase Cancer CenterOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | terminated | N/A | 330 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | terminated | Phase 2 | 24 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | terminated | Phase 1 | 5 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML | terminated | Phase 2 | 3 | Milton S. Hershey Medical CenterOTHER | 1 | Dec 16, 2020 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02782403 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | terminated | Phase 1 / Phase 2 | 15 | PrECOG, LLC.OTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | terminated | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT03152526 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR | terminated | N/A | 1 | Miltenyi Biotec B.V. & Co. KGINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 37 | St. Jude Children's Research HospitalOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT02906696 | Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT01636609 | Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma(UFT RT Phase 3) | terminated | Phase 3 | 219 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT02109627 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | terminated | Phase 1 | 17 | C. Babis AndreadisOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | terminated | Phase 2 | 6 | Medical College of WisconsinOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults(Japanese AML) | terminated | Phase 1 | 9 | Gilead SciencesINDUSTRY | 1 | Mar 6, 2020 | clinicaltrials |
| NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | terminated | Phase 1 | 23 | Polaris GroupINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02341495 | Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65(EXJADE) | terminated | Phase 2 | 4 | Elizabeth HenryOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 | 35 | ADC Therapeutics S.A.INDUSTRY | 1 | Feb 26, 2020 | clinicaltrials |
| NCT00939653 | T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) | terminated | Phase 2 | 6 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | terminated | Phase 1 / Phase 2 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT02370888 | Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease(UF-BMT-MRD-101) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02226497 | Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy | terminated | N/A | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | terminated | N/A | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT02435550 | iCare for Cancer Patients | terminated | N/A | 136 | University of FloridaOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | terminated | Phase 1 | 12 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02174445 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years(DECLINE) | terminated | Phase 3 | 14 | Prof. Dr. Nikolas von BubnoffOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT02954653 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 8 | PfizerINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 7 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 6, 2021source: clinicaltrials